Cineverse Corp., an entertainment technology company, will announce its financial results for the second quarter of fiscal year 2027 on November 13, 2026, before the market opens. The company will hold a conference call at 8:30 a.m. ET to discuss the results, accessible online for investors and the public. Cineverse is known for its innovative Matchpoint® technology and diverse content distribution across multiple platforms. This earnings update will provide insights into the company's performance and strategic direction in the evolving entertainment industry.
Cineverse's upcoming Q2 fiscal 2027 results provide context for media sector activity on Pluang as of Nov 06, 2026 20:21 WIB. Among 57 priced media-sector US stocks, 21 rose and 32 fell. Notable movers include DJT at USD 4.13 with a 1-day change of +2.74% and a typical hold time of 18 days, RUM at USD 4.82 gaining +2.56% with 100% buy order activity, and NFLX at USD 64.00 down -2.38% with a typical hold time of 128 days.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
